Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996333 · ClinicalTrials.gov registry record · Phase 2
Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00996333 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 46 participants.
The verdict
NCT00996333, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study is designed to determine whether an investigational drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer.
Interventions
- DRUG Gemcitabine, Docetaxel, Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996333
The ClinicalTrials.gov registry entry for NCT00996333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Docetaxel, Capecitabine is the first listed.
NCT00996333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996333 about?
NCT00996333 is a clinical study titled "Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)". This study is designed to determine whether an investigational drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic can...
What is the current status of trial NCT00996333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-06. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00996333?
The interventions under investigation include: Gemcitabine, Docetaxel, Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00996333?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.